Can-Fite BioPharma Ltd. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate
Can-Fite BioPharma Ltd. (CANF) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate of 4.64% for the 0-month period ending 2024-05-07, per its 6-K filed 2024-08-29.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate · last filed 2024-08-29
- 2024-05-07: Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 0 month 4.64%.
- 2021-04-13: Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 0 month 1.22%.
- 2020-05-27: Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 1 month 0.93%.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 0 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 1 month |
|---|---|---|
| 2024-05-07 | 4.64% 6-K · filed 2024-08-29 | |
| 2021-04-13 | 1.22% 6-K · filed 2021-08-26 | |
| 2020-05-27 | 0.93% 6-K · filed 2020-08-27 |